Results 181 to 190 of about 22,516 (228)
Some of the next articles are maybe not open access.
Nihon rinsho. Japanese journal of clinical medicine, 2014
Cabazitaxel, new chemotherapeutic agent for castration resistant prostate cancer (CRPC) treated after docetaxel, was developed. In addition, new hormonal drugs for CRPC, such as enzalutamide and abiraterone were also approved in Japan recently. Treatment strategy for CRPC using these drugs is still controversial, therefore we need much more clinical ...
Seiichiro, Ozono, Hiroshi, Furuse
openaire +1 more source
Cabazitaxel, new chemotherapeutic agent for castration resistant prostate cancer (CRPC) treated after docetaxel, was developed. In addition, new hormonal drugs for CRPC, such as enzalutamide and abiraterone were also approved in Japan recently. Treatment strategy for CRPC using these drugs is still controversial, therefore we need much more clinical ...
Seiichiro, Ozono, Hiroshi, Furuse
openaire +1 more source
2018
CRPC had been considered to be chemoresistant until 2004 when docetaxel was approved by US Food and Drug Administration (FDA) as a first-line treatment for metastatic castration-resistant prostate cancer. Thereafter, docetaxel has become the standard treatment for patients with metastatic CRPC.
openaire +1 more source
CRPC had been considered to be chemoresistant until 2004 when docetaxel was approved by US Food and Drug Administration (FDA) as a first-line treatment for metastatic castration-resistant prostate cancer. Thereafter, docetaxel has become the standard treatment for patients with metastatic CRPC.
openaire +1 more source
2018
Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and ...
Takeo Kosaka, Mototsugu Oya
openaire +1 more source
Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and ...
Takeo Kosaka, Mototsugu Oya
openaire +1 more source
Metastasiertes CRPC: Endothelinrezeptor-Blocker?
Im Focus Onkologie, 2013Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC) haben heute verschiedene Second-line-Optionen. Ein weiterer moglicher Ansatz konnte die Intervention an der Endothelin-Achse sein.
openaire +1 more source
Abiraterone and its place in the treatment of metastatic CRPC
Nature Reviews Clinical Oncology, 2012An update of the COU-AA-301 study confirms a survival advantage with abirateroneāprednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.
Oliver, Sartor, Sumanta K, Pal
openaire +2 more sources
Corticosteroid Therapy for CRPC
2018Corticosteroids have been used in the management of castration-resistant prostate cancer (CRPC) as a monotherapy or in combination with abiraterone acetate, docetaxel, or cabazitaxel. Several corticosteroids with varied potencies are used at different doses in daily medical practice.
openaire +1 more source
Alternative Antiandrogen Therapy for CRPC
2018Androgen deprivation therapy continues to be a mainstream treatment for prostate cancer. Failure after initial hormonal treatment including combined androgen blockade (CAB)/maximum androgen blockade (MAB) does not necessarily imply treatment-refractory disease progression. Antiandrogen withdrawal syndrome (AWS) is a manifestation of a prostate-specific
Takanobu Utsumi +4 more
openaire +1 more source
Skeletal Complications in Patients with CRPC
2018Skeletal complications in patients with prostate cancer can result in significant morbidity. There is a relatively high prevalence of bone metastasis and reduction of bone mineral density due to androgen deprivation therapy, and together, these can result in the development of multiple skeletal complications in patients with prostate cancer.
Takamitsu Inoue, Tomonori Habuchi
openaire +1 more source
Radiopharmaceutical Therapy in Metastatic CRPC
2018Radiopharmaceuticals are used in the treatment of metastatic castration-resistant prostate cancer. In the United States, four bone-seeking radiopharmaceuticals have been approved. Three of these are Ī²-emitters approved for palliative purposes (phosphorus-32, strontium-89, samarium-153-ethylenediamine tetramethylene phosphonic acid).
Kwang Suk Lee, Byung Ha Chung
openaire +1 more source